Brief: Mangoceuticals To Introduce “Prime” Powered By Kyzatrex
13/12/2023 12:55
Dec 13 (Reuters) - Mangoceuticals Inc MGRX.O :
* MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️
(CIII
TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL
TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT
Source text for Eikon: ID:nGNX5q2bSH
Further company coverage: MGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mangoceuticals
See all newsBrief: Mangoceuticals And Nuclea Energy Terminate Business Combination Agreement On August 19
Brief: Mangoceuticals Inc.’S Merger Partner, Nuclea Energy, Inc., Enters Into Definitive Agreement To Acquire Moltex Energy’S Advanced Nuclear Technology Assets
NASDAQ RESUMED AT 10:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM
NASDAQ RESUMED AT 10:27 AM